Raymond James Remains a Hold on Galapagos (GLPG)

Raymond James analyst Dane Leone maintained a Hold rating on Galapagos (GLPG) today. The company’s shares closed last Wednesday at $89.90.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 20.2% and a 66.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus Pharmaceuticals, and Allogene Therapeutics.

Currently, the analyst consensus on Galapagos is a Hold with an average price target of $122.08, a 29.0% upside from current levels. In a report released today, Maxim Group also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

Galapagos’ market cap is currently $7.15B and has a P/E ratio of -16.10. The company has a Price to Book ratio of 2.20.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts